Global Oligonucleotide Therapy-based Drug Supply, Demand and Key Producers, 2023-2029

Global Oligonucleotide Therapy-based Drug Supply, Demand and Key Producers, 2023-2029

The global Oligonucleotide Therapy-based Drug market size is expected to reach $ 84010 million by 2029, rising at a market growth of 3.6% CAGR during the forecast period (2023-2029).

The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.

Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.

This report studies the global Oligonucleotide Therapy-based Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Oligonucleotide Therapy-based Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oligonucleotide Therapy-based Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Oligonucleotide Therapy-based Drug total market, 2018-2029, (USD Million)

Global Oligonucleotide Therapy-based Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Oligonucleotide Therapy-based Drug total market, key domestic companies and share, (USD Million)

Global Oligonucleotide Therapy-based Drug revenue by player and market share 2018-2023, (USD Million)

Global Oligonucleotide Therapy-based Drug total market by Type, CAGR, 2018-2029, (USD Million)

Global Oligonucleotide Therapy-based Drug total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Oligonucleotide Therapy-based Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech and Pfizer, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oligonucleotide Therapy-based Drug market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Oligonucleotide Therapy-based Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Oligonucleotide Therapy-based Drug Market, Segmentation by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA

Global Oligonucleotide Therapy-based Drug Market, Segmentation by Application
Neuromuscular Diseases
hATTR
COVID-19
Other

Companies Profiled:
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

Key Questions Answered

1. How big is the global Oligonucleotide Therapy-based Drug market?

2. What is the demand of the global Oligonucleotide Therapy-based Drug market?

3. What is the year over year growth of the global Oligonucleotide Therapy-based Drug market?

4. What is the total value of the global Oligonucleotide Therapy-based Drug market?

5. Who are the major players in the global Oligonucleotide Therapy-based Drug market?